FIG. 1



-35%
42.1
18.5
6.3
5.8
-0.4
-0.8
-14.8
-15.8
-16.1
-16.4
-17.1
-20.8
-23.5
-24.6
-26.6
-29.3
-33.7
-34.3
-34.5
-36.2
-38.6
-40.2
-41.2
-43.8
-44.3
-50.1
-54.4
-57.8
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
Percentage Change From Baseline
Patients (N=28)

FIG. 2



PK
PD
Absorption lag
Navitoclax
ALAG1
Central
Peripheral
Proliferation
POOL
Maturation 1
Maturation 2
Maturation 3
Total Platelets
Platelet 1
Platelet 2
Absorption lag
Ruxolitinib
ALAG2
Central
Peripheral
zero order production
Feedback
Ruxolitinib
(-) Inhibition
Navitoclax
(+) Stimulation
Platelet Prediction = Baseline · Platelet 1 · Platelet 2

FIG. 3A



Naive
R/R
N=100
N=19
N=59
N=22
N=36
N=52
N=12
Overall
>300-500
>150-300
100-150
Baseline Group
100->200mg
300mg
200mg
100mg
36.0%
46.5%
38.2%
25.8%
12.6%
18.9%
12.9%
6.4%
44.7%
58.1%
47.8%
31.0%
82.2%
92.7%
87.2%
76.0%
31.9%
44.3%
35.5%
23.7%
14.7%
22.3%
15.6%
8.3%
43.8%
60.9%
49.7%
33.4%
82.4%
93.7%
88.5%
78.7%
0
20
40
60
80
100
Percent subjects with Grade 3 Thrombocytopenia
Regimen
100->200mg
100mg
200mg
300mg

FIG. 3B



Naive
R/R
N=100
N=19
N=59
N=22
N=36
N=52
N=12
Overall
>300-500
>150-300
100-150
Baseline Group
100->200mg
300mg
200mg
100mg
5.9%
11.6%
8.0%
4.1%
1.2%
2.0%
1.3%
0.6%
6.7%
12.8%
8.4%
4.2%
21.2%
45.0%
33.2%
17.9%
4.5%
9.8%
6.9%
3.5%
1.4%
2.3%
1.6%
0.9%
6.0%
13.7%
9.6%
4.4%
20.1%
45.5%
32.6%
19.4%
0
20
40
Percent subjects with Grade 4 Thrombocytopenia
Regimen
100->200mg
100mg
200mg
300mg

FIG. 4



Absorption lag
Ruxolitinib
ALAG2
Central
Peripheral
Navitoclax
ALAG1
Spleen Volume
Ruxolitinib (-) Inhibition
Navitoclax (-) Inhibition
PK
PD

FIG. 5



Change from baseline
Continuous dosing assumed
DoseNav: 100mg
DoseNav: 200mg
DoseNav: 300mg
DoseRux: 5mg
DoseRux: 10mg
DoseRux: 15mg
DoseRux: 20mg
-18.3%
-21.3%
-23.8%
-23.4%
-25.1%
-27.4%
-26.2%
-28.0%
-30.4%
-27.6%
-30.0%
-31.9%
-35%
Average Change from Baseline of Spleen Volume
0
-25
-50
0
12
24
36
Week
Areas depict 5th, 25th, 75th and 95th percentile (N~5000/arm), incl. observational error

FIG. 6




Percent subjects with SVR35
Continuous dosing assumed
DoseNav 100mg
DoseNav 200mg
DoseNav 300mg
10% diff
%subjects with SVR35
Week
DoseRux
5mg
10mg
15mg
20mg
N=500/arm; incl. observational error

FIG. 7


Patients with 1° or 2° MF
Eligibility Screen
Cohort 1a (N= 34) Currently treated with ruxolitinib
Cohort 1b (N= ~70) Received treatment with JAK-2 inhibitor
Cohort 2 (N= ~30) Received treatment with JAK-2 inhibitor
Cohort 3 (N= ~30) No prior JAK-2 inhibitor therapy
Navitoclax QD
Cohort 1a: 50/100/200/300 mg QD
Cohorts 1b, 2 & 3: 200 mg QD starting dose
+
Ruxolitinib BID
(Cohorts 1a, 1b & 3 only)
Continue until loss of clinical benefit or unacceptable toxicity
Treatment Discontinuation
Follow-Up for Post-Therapy and Survival